AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio has raised $18.4M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
AnaCardio's investors include Novo Holdings, Pureos Bioventures, Sound Bioventures, Karolinska, Industrifonden.
AnaCardio is headquartered in Solna, Sweden.
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AnaCardio — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/anacardio. Accessed September 15, 2026.
VCBacked. (2025). AnaCardio — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/anacardio
{{cite web |title=AnaCardio — Funding & Investors |url=https://www.vcbacked.co/company/anacardio |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated